Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
7.47
-0.01 (-0.13%)
At close: Jun 18, 2025, 4:00 PM
7.26
-0.21 (-2.81%)
After-hours: Jun 18, 2025, 7:31 PM EDT
Arvinas Employees
Arvinas had 430 employees as of December 31, 2024. The number of employees decreased by 15 or -3.37% compared to the previous year.
Employees
430
Change (1Y)
-15
Growth (1Y)
-3.37%
Revenue / Employee
$992,791
Profits / Employee
-$108,372
Market Cap
545.25M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
ARVN News
- 6 days ago - Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress - GlobeNewsWire
- 13 days ago - Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer - GlobeNewsWire
- 14 days ago - Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting - GlobeNewsWire
- 19 days ago - Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression - Reuters
- 19 days ago - Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer - GlobeNewsWire
- 20 days ago - Arvinas to Present at Jefferies Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Shareholders to Inquire about Securities Investigation - Accesswire
- 5 weeks ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Shareholders to Connect - Accesswire